Some promising results were obtained by targeting the hepcidin/IL-6 axis, or the hepcidin/IL-8 axis, leading to decreased metastasis of breast cancer to the liver, lymph nodes, and lungs, while anti-TfR antibodies were only effective in some patients and in certain cancer subtypes, whereby anemia was reported as an important side-effect [57,58,59]. This evidence concerns the gene TFRC and breast cancer.